Phase II study assessing the effect of carfilzomib treatment on early free light chain kinetics in myeloma patients with renal impairment

Australiasian Leukemia and Lymphoma Group0 个研究点目标入组 38 人开始时间: 2014年3月21日最近更新: 2023年7月18日

试验速览

阶段: 2 期
状态: 已完成
发起方
入组人数: 38

研究概览研究设计入排标准研究者记录与标识符相似试验

研究概览

简要总结

暂无简介。

研究设计

研究类型: Interventional
分配方式: Non-randomised trial
主要目的: Treatment

入排标准

年龄范围: 18 Years 至 o limit（—）
性别: All

入选标准

•All of the following criteria must be satisfied for enrolment in the study.
•Male and Female patients, >=18 years of age
•Patients with newly diagnosed MM (diagnosis of MM as per IMWG –21)
•Multiple myeloma with relapsing or progressing disease at study entry,
•With either
•Measurable M-component in serum or urine,
•In patients with no detectable M-component, an abnormal FLC ratio on the Serum FLC assay
•For IgA patients whose disease can only be reliably measured by serum quantitative immunoglobulin (qIgA) >= 750 mg^dL (0.75 g^dL).
•Patients with acute renal injury as the cause of reduced renal function, with creatinine clearance 15-40 ml^min at screening (calculated by the CKD-EPI and MDRD formulae)
•Difference between involved and uninvolved free light chain >=300 mg^L
•Adequate liver function (total bilirubin < 1.5 ULN, ALT < 2.5x ULN)
•Absolute neutrophil count >= 1.0 x 109^L within one week of starting therapy.
•Platelet count >= 50 x 109^L (>= 30 x 109^L if myeloma involvement in the marrow is greater than 50%) within one week of starting therapy, patients should not have received platelet transfusions within one week of the screening platelet count
•Hb >= 80g^L, red cell transfusions as per institutional protocol are allowed
•Subject must have LVEF >= 40%, determined by 2-D transthoracic echocardiogram (ECHO) is the preferred method of evaluation. Multigated Acquisition Scan (MUGA) is acceptable if ECHO is not available.
•Has provided written informed consent
•Males capable of parenting a child and females of childbearing potential must be using a medically acceptable and adequate method of contraception while undergoing protocol treatment and for 12 weeks after the last treatment

排除标准

•Presence of any of the following criteria will exclude the subject from enrolment in the study.
•Patients who have had myocardial infarction within 6 months prior to enrolment, or NYHA (New York Hospital Association) Class III or IV heart failure, uncontrolled angina, severe uncontrolled ventricular arrhythmias, electrocardiographic evidence of acute ischemia or active conduction system abnormalities at any time.
•Other uncontrolled intercurrent illness including, but not limited to, severe active infection, or psychiatric illness/social situations that would limit compliance with study requirements
•Evidence of infection, dehydration or hypercalcaemia as the cause of acute kidney injury that has not been corrected.
•Patients on dialysis at Screening.
•Patients with known amyloidosis.
•Patients with myelodysplastic syndrome.
•Known history of allergy to Captisol (a cyclodextrin derivative used to solubilise carfilzomib)
•Patients with contraindication to dexamethasone.
•Contraindication to any of the required concomitant drugs or supportive treatments, including hypersensitivity to antiviral drugs, or intolerance to hydration due to pre-existing pulmonary or cardiac impairment.
•Women who are pregnant or lactating. Females of child-bearing potential must have a negative urine pregnancy test at Screening.
•Known Hepatitis B, Hepatitis C, HIV infection, other immunosuppressive therapy including dexamethasone or autoimmune disease
•Prior diagnosis of cancer that was:
•more than 5 years prior to current diagnosis with subsequent evidence of disease recurrence or clinical expectation of recurrence is greater than 10%.
•within 5 years of current diagnosis with the exception of successfully treated basal cell or squamous cell skin carcinoma or carcinoma in situ of the cervix.
•Participation in other therapeutic studies in the last 60 days except for studies with a non-medical intervention. Documented evidence of receiving placebo will be required.
•Presence of any psychological, familial, sociological or geographical condition potentially hampering compliance with the study protocol and follow-up schedule. This condition must be discussed with the patient prior to signing consent and registration in the trial.

研究者

发起方

Australiasian Leukemia and Lymphoma Group

相似试验

招募中

2 期

Study to evaluate the effectiveness of a combination of 3 treatments, followed by transplantation of their own blood cell progenitor cells for patients under 70 years of age with asymptomatic multiple myeloma at high risk of developing into symptomatic myeloma

2024-516908-42-00Fundacion PETHEMA90

尚未招募

2 期

Phase 1b/2 Study of Carfilzomib in Combination With Induction Chemotherapy in Children With Relapsed or Refractory Acute Lymphoblastic LeukemiaAcute Lymphoblastic LeukemiaCancer of White Blood Cells10024324

NL-OMON56393Amgen1

进行中（未招募）

1 期

Phase 1b/2 Study of Carfilzomib in Combination with Induction Chemotherapy in Children with Relapsed or Refractory Acute Lymphoblastic Leukemia

EUCTR2014-001633-84-ROOnyx Therapeutics, Inc., an Amgen Inc. subsidiary144

进行中（未招募）

1 期

Phase 1b/2 Study of Carfilzomib in Combination with Induction Chemotherapy in Children with Relapsed or Refractory Acute Lymphoblastic LeukemiaRelapsed or Refractory Acute Lymphoblastic LeukemiaMedDRA version: 21.0Level: LLTClassification code 10025230Term: Lymphatic leukemiaSystem Organ Class: 100000004864

EUCTR2014-001633-84-ATOnyx Therapeutics, Inc., an Amgen Inc. subsidiary144

进行中（未招募）

1 期

EUCTR2014-001633-84-SEOnyx Therapeutics, Inc., an Amgen Inc. subsidiary144